FMO5 and persistent fetal circulation syndrome: In addition, experimental evidence on HIF1α inhibition (136, 137), hydrocortisone (138), superoxide dismutase (SOD) (139), NADPH oxidase inhibitor (Apocynin) (140), and other agonists and antagonists that influence neonatal PPHN (133) have been reported.